Pharma-bio Serv, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Pharma-Bio Serv, Inc. announced its financial results for the second quarter of fiscal year 2026, reporting an increase in net income and revenues, driven by growth in its Puerto Rico consulting segment.
OQB
Pharma-Bio Serv, Inc. reported a significant increase in net income for the first quarter of fiscal year 2026 despite a slight decline in overall revenues, driven by improved gross profit margins and higher other income.
OQB
Pharma-Bio Serv, Inc. reported a significantly reduced net loss for the nine months ended July 31, 2025, driven by improved gross profit margins and reduced operating expenses, despite a slight revenue decline.
OQB
10-Q: Pharma-Bio Serv Swings to Profit in Q2 2025 Amidst Strong European Growth and Improved Margins
Pharma-Bio Serv, Inc. reported a significant turnaround in its financial performance for the second quarter and first six months of fiscal year 2025, achieving net income driven by robust European market expansion and enhanced gross profit margins, despite revenue declines in other key regions.
OQB
Pharma-Bio Serv, Inc. reports a net income of $8,536 for the quarter ended January 31, 2025, a significant improvement compared to a net loss of $270,719 in the same period last year, driven by increased gross profit margins in the European market.
OQB
Pharma-Bio Serv experienced a significant decrease in revenue and a net loss for the third quarter of 2024, primarily due to reduced project activity in key markets.
OQB
Pharma-Bio Serv experienced a significant decrease in revenue and a net loss for the quarter ended April 30, 2024, compared to the same period last year.
OQB
Pharma-Bio Serv, Inc. reported a net loss for the first quarter of 2024, primarily due to a significant decrease in revenue compared to the same period last year.